Testing a new injection to help kidney dialysis patients with overactive parathyroid glands

Plain-English translation of NCT06976177 on ClinicalTrials.gov ↗ · Source last updated May 2025 · Translation generated July 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This study is testing a new medication called to treat secondary hyperparathyroidism, a condition where your parathyroid glands become overactive as a result of kidney disease and dialysis. The medication is given as an injection three times per week, and researchers want to see if it safely lowers the levels of parathyroid hormone in your blood.

People on dialysis often struggle with overactive parathyroid glands, which can lead to bone problems and other serious complications. This trial is testing whether this new treatment can better control parathyroid hormone levels and help keep you healthier.

Do you qualify?

You likely qualify if…

you are at least 18 years old
you have been on dialysis (three times a week, or five times in two weeks) for at least three months
you have been diagnosed with secondary hyperparathyroidism related to kidney disease
you are able to read and understand the study information and willing to give your informed consent
your dialysis center uses dialysate with a calcium concentration of at least 1.25 mmol/L

You likely don't qualify if…

you have primary hyperparathyroidism (rather than secondary hyperparathyroidism)
you are currently taking calcimimetic medications like cinacalcet or etelcalcetide and cannot stop taking them
you have had gastrointestinal bleeding within the past six months
you have had your parathyroid glands surgically removed within the past six months or plan to have surgery during the study
you have a history of seizures or are currently being treated for epilepsy

What participation looks like

You would receive the medication as an intravenous injection three times per week during your regular dialysis sessions. The study has two parts: Part A lasts 52 weeks and Part B lasts 26 weeks, depending on which group you're in. Throughout the study, you'll have regular blood tests and visits to check how well the medication is working and to monitor for any side effects.

AI-generated summary from trial data · Jul 2, 2026 · Not medical advice

Trial locations(1 site)

China

First Affiliated Hospital College of Medicine, Zhejiang University, Hangzhou, Zhejiang